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Abstract
Introduction
Very few studies have examined the potential spill-over effect of a trial intervention in gen-
eral practice. We investigated whether training and support of general practitioners in the
intensive treatment of people with screen-detected diabetes improved rates of redeemed
medication, morbidity and mortality in people with clinically-diagnosed diabetes.
Methods
This is a secondary, post-hoc, register-based analysis linked to a cluster randomised trial. In
the ADDITION-Denmark trial, 175 general practices were cluster randomised (i) to routine
care, or (ii) to receive training and support in intensive multifactorial treatment of individuals
with screen-detected diabetes (2001 to 2009). Using national registers we identified all indi-
viduals who were diagnosed with clinically incident diabetes in the same practices over the
same time period. (Patients participating in the ADDITION trial were excluded). We com-
pared rates of redeemed medication, a cardiovascular composite endpoint, and all-cause
mortality between the routine care and intensive treatment groups.
Results
In total, 4,107 individuals were diagnosed with clinically incident diabetes in ADDITION-
Denmark practices between 2001 and 2009 (2,051 in the routine care group and 2,056 in
the intensive treatment group). There were large and significant increases in the proportion
of patients redeeming cardio-protective medication in both treatment groups during follow-
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up. After a median of seven years of follow-up, there was no difference in the incidence of a
composite cardiovascular endpoint (HR 1.15, 95% CI 0.95 to 1.38) or all-cause mortality
between the two groups (HR 1.08, 95% CI 0.94 to 1.23).
Discussion
There was no evidence of a spill-over effect from an intervention promoting intensive treat-
ment of people with screen-detected diabetes to those with clinically-diagnosed diabetes.
Overall, the proportion of patients redeeming cardio-protective medication during follow-up
was similar in both groups.
Trial Registration
ClinicalTrials.gov NCT00237549
Introduction
The benefit of managing cardiovascular risk factors among people with type 2 diabetes is well
established [1]. However, effective implementation of evidence-based treatment is challenging.
Studies suggest that many patients do not receive care according to current guidelines [2].
Changing health practitioner behaviour and their treatment schemes is not straightforward [3].
To improve the process of diabetes care, multifaceted professional interventions and organisa-
tional interventions that facilitate structured and regular review of patients have been shown to
be effective in improving implementation of evidence-based treatment among clinicians [4].
In the Danish arm of the ADDITION trial, 175 general practices were cluster randomised to
routine care or to receive training and support in the implementation of an intensive diabetes
treatment program for individuals with screen-detected diabetes [5]. The ADDITION trial
intervention was associated with a significant increase in redeemed cardio-protective medica-
tion and a non-significant 17% risk reduction in CVD events over five-years of follow-up [6].
Given the positive changes we managed to affect in health practitioner behaviour in the inten-
sive treatment practices, we wanted to investigate whether the education and guidelines we
offered them may also have had an impact on the management of patients with clinically-diag-
nosed diabetes. In the few studies which have examined the potential spill-over effect of a trial
intervention in general practice, one found that no evidence for a spill-over effect in treatment
from diabetes patients to those at high risk of developing diabetes [7], while another showed a
positive change in practitioner behaviour in both control and intervention groups [8].
In order to assess a potential spill-over effect of the trial intervention among practices tak-
ing part in ADDITION-Denmark, we used national registry data to compare rates of redeemed
cardio-protective medication, morbidity and mortality among people with clinically-diag-
nosed diabetes in the routine care and intensive treatment trial groups.
Materials and Methods
Study design–The ADDITION trial
ADDITION-Denmark consists of two phases: (i) a pragmatic screening programme, and (ii) a
cluster-randomised parallel-group trial comparing the effects of intensive multifactorial treat-
ment with routine care among individuals with screen-detected type 2 diabetes [5,6]. In brief,
between 2001 and 2006, we performed a population-based stepwise screening programme
Investigation of a Spill-Over Effect in a Cluster RCT
PLOS ONE | DOI:10.1371/journal.pone.0170697 February 2, 2017 2 / 11
Annelli Sandbæk, Institute of Public Health, Aarhus
University (annelli.sandbaek@ph.au.dk). Data from
DST were made available after an application
procedure at DST (http://www.dst.dk/en/TilSalg/
Forskningsservice). Data from ADDITION and DST
were merged by DST and analyses were performed
via a secure VPN connection. Due to the Danish
Act of processing of personal data, future
interested researchers have to perform the above-
mentioned steps to obtain access to the data.
Funding: MC has received an unrestricted Post
Docteral grant to the project: "Type 2 diabetes
treatment in Danish Primary Care – Are we
reaching the Triple Aim?" from the Novo Nordisk
Foundation, NNF14OC0008981.
Competing Interests: MC is supported by the Novo
Nordisk Foundation. DRW and RKS are supported
by the Danish Diabetes Academy, which is funded
by the Novo Nordisk Foundation. DRW reports
receiving lecture fees from Novo Nordisk A/S and
Steno Diabetes Center. DRW and TL hold shares in
Novo Nordisk A/S. TL reports receiving a fee for
attending an international board meeting for Astra
Zeneca on early detection and treatment of
diabetes in 2015. AS reports receiving lecture fees
for providing continuing medical education to GPs.
SJG’s research programme is supported by MRC
Epidemiology Unit core funding (MC_UU_12015/
4). SJG is an NIHR Senior Investigator and
member of the NIHR School for Primary Care
Research. SJG receives an honorarium and
reimbursement of travel expenses from Eli Lilly
associated with membership of an independent
data monitoring committee for a randomised trial
of a medication to lower glucose. SJG received an
honorarium from Janssen for speaking at an
educational meeting in 2015. This does not alter
our adherence to PLOS ONE policies on sharing
data and materials.
among people aged 40 to 69 years without known diabetes in 175 general practices in Den-
mark. Participants diagnosed with type 2 diabetes were subsequently managed according to
the treatment regimen to which their practice had been allocated: routine care or intensive
treatment [9]. Ethical approval for the trial was granted by the Region Midt Ethical Commit-
tee, Denmark. This study was approved by the Danish Data Protection Agency and the Danish
Health and Medicine Authority.
Intervention
GPs and nurses received training and support in delivering intensive treatment via small
group or practice-based educational meetings where treatment targets / algorithms, lifestyle
advice, and supporting evidence were discussed. Patient audit and feedback was completed in
face-to-face meetings held up to twice a year or was coordinated by post. Intensive treatment
practices received additional funding to support the delivery of care, which included target-
driven management of hyperglycaemia, blood pressure, and cholesterol levels by medical treat-
ment and promotion of healthy lifestyles, based on the stepwise regimen used in the Steno-2
study and other trial results[6,9].
In the routine care group, general practitioners were advised to follow Danish national rec-
ommendations on diabetes treatment [10,11] and received no further follow-up.
Study population
This is a secondary, post-hoc, register-based analysis linked to the ADDITION-Denmark trial.
In order to assess the potential spill-over effect of the intervention, we identified individuals
who were diagnosed with clinically incident diabetes in the same 175 GP practices taking part
in ADDITION-Denmark over the same time period as the intervention of the trial (2001 to
2009), using the target population from the ADDITION-Denmark (all patients between 40 and
69 years, n = 163,189). Our definition of clinically diagnosed diabetes was a proxy measure
based on two different modes of identification. Participants were defined as having diabetes if
they fulfilled at least one of the following criteria: (i) included on the Danish National Patient
Register with a diagnosis of diabetes (ICD-8: 249, 250; ICD-10: E10-14, H36.0, O24, excluding
O24.4); or (ii) redeemed glucose-lowering medication at least twice within six months during
the study period (2001 to 2008). Patients with screen-detected diabetes who participated in the
ADDITION trial were excluded. The practice and participants flow are shown in Fig 1.
We linked information about individuals with clinically incident diabetes to other Danish
registers using unique civil registration numbers. We retrieved information on age, sex, educa-
tion, marital status and redeemed cardio-protective medication (Danish National Prescription
Registry[12]). Education was categorised according to Unesco’s International Standard Classi-
fication of Education19. We calculated the score for the Charlson Comorbidity Index[13] using
information from the Danish National Patient Register from 10 years before inclusion in the
study.
Outcomes
Participants were followed for a median of 7.3 years to 31st December 2013, when national reg-
isters were searched for information on vital status and incident CVD events. For death, the
primary outcome was all-cause mortality (based on underlying cause of death). We used a
composite of first event of cardiovascular death, non-fatal MI (ICD-10 codes I20 to I25, and
I46) or non-fatal stroke (ICD-10 code I60-69, G45) to delineate an incident CVD event. Data
on incident CVD events was gathered from the National Patient Registry, which records all in-
patient and out-patient hospitalisations in Denmark.
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Statistical analysis
Baseline characteristics were summarised separately in the intensive treatment and routine
care trial groups. Patient groups were compared using the χ2 test for categorical variables and
the t test for continuous variables. P-values<0.05 were considered statistically significant.
Fig 1. Flow of GP-Practices included in the Danish arm of the ADDITION trial and number of patients identified with clinically incident diabetes
from the Danish National Diabetes Register (DNDR) during the intervention period of the ADDITION trial (2001–2009). *Patients with screen-detected
diabetes included in the ADDITION Trial. Pts = patients.
doi:10.1371/journal.pone.0170697.g001
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Date of entry to the study was date of diagnosis of clinically-incident diabetes. Individuals
were censored on the date of first event, death, emigration or 31/12/2013, whichever was earli-
est. Hazard ratios comparing mortality and incident CVD events between the groups were
estimated with a Cox proportional hazards regression model. We used a Nelson-Aalen hazard
function to generate a cumulative incidenc curve based on this model. Since allocation to the
treatment groups was at the practice level, robust standard errors were calculated that take into
account the two-level structure of the data, using the “cluster()” option in Stata. We adjusted
for age, sex and the Charlson Comorbidity Index Score. In a sensitivity analysis, we further
adjusted for education level among those with complete data for this variable (118 people had
missing data for education). We calculated the proportion of participants who redeemed pre-
scriptions for six cardio-protective medication classes in both groups during the following
times periods: 0 to 12 months before clinical diagnosis of diabetes, from 01/07/2008 to 30/06/
2009, and from 01/01/2012 to 31/12/2012. All analyses were completed using Stata Version
14.1 (STATA Corp., College Station, Texas, USA).
Results
Table 1 shows the characteristics of individuals diagnosed with clinically-incident diabetes
from ADDITION-Denmark practices between 2001 and 2009. The mean age (SD) of the cohort
was 59.6 (8.2) years and 41% were female. Levels of education, marital status and the Charlson
Comorbidity Index score were similar between the trial groups.
Table 1. Characteristics of individuals diagnosed with clinically-incident diabetes between 2001 and 2009 in ADDITION-Denmark general prac-
tices, by trial group.
Intensive treatment trial group (n = 2,056) Routine caretrial group (n = 2,051) p-value
Female sex, n (%) 843 (41.0) 850 (41.4) 0.79
Age group (years), n (%)
- 30–39 0 (0.) 3 (0.2) 0.29
- 40–49 301 (14.6) 4.6)
- 50–59 728 (35.4) 4.5)
- 60–69 801 (39.0) 0.8)
-70 226 (11.0) 206 (10.0)
Mean age group (SD), years 59.6 (8.2) 59.6 (8.1) 1.00
Education level, n (%)
- 10 years 892 (44.7) 850 (42.6) 0.31
- 10 to 15 years 828 (41.5) 3.9)
- >15 years 275 (13.8) 269 (13.5)
Married, n (%) 1,463 (76.0) 1,495 (77.8) 0.17
Charlson Comorbidity Index Scorea, n (%)
- 0 1,552 (75.5) 1,582 (77.1) 0.64
- 1 321 (15.6) 4.3)
- 2 111 (5.4) .3)
-3 72 (3.5) 67 (3.3)
Year of clinically-incident diabetes diagnosis, n (%)
- 2001–2002 221 (10.8) 222 (10.8) 0.33
- 2003–2004 576 (28.0) 8.4)
- 2005–2006 595 (28.9) 6.5)
- 2007–2008 664 (32.3) 703 (34.3)
a The Charlson Comorbidity Index Score included all 19 diseases except for diabetes. Patient groups were compared using the χ2 test for categorical
variables and the t test for continuous variables.
doi:10.1371/journal.pone.0170697.t001
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Patterns of redeemed medication during follow-up are shown in Table 2. Before clinical
diagnosis of diabetes, treatment groups redeemed similar proportions of anti-hypertensive,
lipid-lowering, anti-depressant and anti-psychotic medication. However, the intensive treat-
ment group redeemed higher levels of glucose-lowering and anti-thrombotic medication
before diagnosis compared to the routine care group. During the follow-up period, there were
large and statistically significant increases in the proportion of patients redeeming cardio-pro-
tective medication in both treatment groups. By the end of follow-up there were similar levels
of cardio-protective medication in the two groups, although higher rates of redeemed anti-
thrombotic medication persisted in the intensive treatment group. There were small increases
in the proportion of the study population redeeming anti-depressant medication over time,
and no change in the proportion receiving anti-psychotic medication.
The median (IQR) duration of follow-up was 7.3 years (5.7, 9.4). During follow-up, there
were 289 cardiovascular events (14.1%) in the intensive treatment group (incidence (95% CI):
20.7 (18.4; 23.2 per 1,000 person-years) and 258 events (12.6%) in the routine care group (inci-
dence (95% CI): 18.4 (16.3; 20.8) per 1,000 person-years) (Table 3). Following adjustment,
there was no significant difference in incident CVD between the intensive treatment and rou-
tine care groups (HR 1.15,95% CI: 0.95 to 1.38) (Fig 2).
Table 2. Rates of redeemed cardio-protective medication over time among individuals diagnosed with clinically-incident diabetes between 2001
and 2009 in ADDITION-Denmark general practices, by trial group.
Intensive treatment trial group (n = 2,056)1 Routine care trial group (n = 2,051)1 p-value
n (%) n (%)
Anti-hypertensive medication
0–12 months before clinical diagnosis of diabetes 1,312 (63.8) 1,262 (61.5) 0.13
From 01/07/2008 to 30/06/2009 1,486 (78.3) 1,486 (78.9) 0.65
From 01/01/2012 to 31/12/2012 1,421 (83.6) 1,418 (82.1) 0.24
Lipid-lowering medication
0–12 months before clinical diagnosis of diabetes 770 (37.5) 714 (34.8) 0.07
From 01/07/2008 to 30/06/2009 1,335 (71.3) 1,304 (68.7) 0.08
From 01/01/2012 to 31/12/2012 1,250 (73.6) 1,259 (72.9) 0.64
Glucose-lowering medication
0–12 months before clinical diagnosis of diabetes 1,149 (55.9) 994 (48.5) 0.00*
From 01/07/2008 to 30/06/2009 1,416 (75.6) 1,385 (73.0) 0.07
From 01/01/2012 to 31/12/2012 1,318 (77.6) 1,350 (78.2) 0.67
Anti-thrombotic medication
0–12 months before clinical diagnosis of diabetes 791 (38.5) 658 (32.1) 0.00*
From 01/07/2008 to 30/06/2009 1,129 (60.3) 1,002 (52.8) 0.00*
From 01/01/2012 to 31/12/2012 1,040 (61.2) 977 (56.6) 0.01*
Anti-depressant medication
0–12 months before clinical diagnosis of diabetes 344 (16.7) 333 (16.2) 0.67
From 01/07/2008 to 30/06/2009 379 (20.2) 376 (19.8) 0.76
From 01/01/2012 to 31/12/2012 347 (20.4) 361 (20.9) 0.72
Anti-psychotic medication
0–12 months before clinical diagnosis of diabetes 124 (6.0) 115 (5.6) 0.58
From 01/07/2008 to 30/06/2009 114 (6.1) 108 (5.7) 0.60
From 01/01/2012 to 31/12/2012 104 (6.1) 95 (5.5) 0.45
1At time of inclusion, thus numbers may not add up to total due to death or censoring. Patient groups were compared using the χ2 test for categorical
variables and the t test for continuous variables.
* Statistically significant difference, P<0.05.
doi:10.1371/journal.pone.0170697.t002
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Table 3. Incidence of all-cause mortality and a composite cardiovascular event among individuals diagnosed with clinically-incident diabetes
between 2001 and 2009 in ADDITION-Denmark general practices, by trial group.
Intensive treatment trial group (n = 2,056) Routine care trial group (n = 2,051) Adjusted hazard
ratios1 (95% CI)Number of
events
Person-years
of follow-up
Rate per
1,000pyrs (95%
CI)
Number of
events
Person-
years follow-
up
Rate per
1,000pyrs (95%
CI)
All-cause mortality 447 14,978 29.8 (27.2 to
32.7)
419 15,022 30.0 (27.2 to
33.0)
1.08 (0.94 to
1.23)
Composite cardiovascular event
(first of CVD death, non-fatal IHD or
non-fatal stroke)
289 13,959 20.7 (18.4 to
23.2)
258 14,044 18.4 (16.3 to
20.8)
1.15 (0.95 to
1.38)
1 Hazard ratios were estimated with a Cox proportional hazards regression model. Robust standard errors were calculated that take into account the two-
level structure of the data and any potential correlation between individuals within practices. Models were adjusted for age, sex, and the Charlson
Comorbidity Index Score.
doi:10.1371/journal.pone.0170697.t003
Fig 2. Cumulative incidence of a composite CVD endpoint (CVD death, non-fatal myocardial infarction or non-fatal stroke) among individuals
diagnosed with clinically-incident diabetes from ADDITION-Denmark general practices by treatment groups from 2001–2012. (Blue line = Intensive
treatment group, Red line = Routine care group).
doi:10.1371/journal.pone.0170697.g002
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During follow-up, there were 447 deaths (21.7%) in the intensive treatment group (mortal-
ity rate (95% CI): 30.0 (27.2; 33.0) per 1,000 person-years) and 419 deaths (20.4%) in the rou-
tine care group (mortality rate (95% CI): 29.8 (27.2; 32.7) per 1,000 person-years). Following
adjustment, there was no significant difference in all-cause mortality between the two groups
(HR 1.08 (95% CI: 0.94 to 1.23)) (Fig 3). There was no difference in the overall result when
adjusting for education level.
Discussion
We found no evidence for a spill-over effect from a multi-faceted intervention promoting the
intensive treatment of people with screen-detected diabetes to those with clinically-diagnosed
diabetes. There was no difference in the risk of incident CVD and mortality between the inten-
sive treatment and routine care groups during seven years of follow-up. Rates of cardio-protec-
tive medication increased significantly over time in both groups.
Fig 3. Cumulative incidence of all-cause mortality among individuals diagnosed with clinically-incident diabetes from ADDITION-Denmark
general practices by the treatment group from 2001–2013. (Blue line = Intensive treatment group, Red line = Routine care group).
doi:10.1371/journal.pone.0170697.g003
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In a previous study examining the experience of individuals found with impaired fasting
glycaemia or impaired glucose tolerance following screening in the ADDITION-Denmark trial,
we showed that the training of general practitioners in intensive treatment of diabetes had no
spill-over effect on these high-risk individuals[7]. There was no difference in rate of change in
risk factor levels or lifestyle behaviours from screening to follow-up between individuals in the
intensive treatment group compared to the routine group. There are very few other studies
examining the spill-over effect of a trial intervention in general practice with which to compare
our results. One study determining the effect of continuing medical education among family
physicians on the quality of clinical care, found that when topics were of relatively great inter-
est to physicians, the control group (who did not receive the continuing education package)
showed as much improvement as the intervention group[8]. In terms of diabetes care, a recent
meta-analysis of trials on quality improvement strategies concluded that interventions solely
targeting health-care professionals seem to be beneficial only if baseline HbA1c control is poor
[14]. This finding was also observed in the ADDITION-Denmark trial [15]. This might be the
case in this study as well. However, we do not have data on HbA1c values from the clinically-
diagnosed individuals in our analysis to complete this sub-group analysis.
There are a further explanations for the lack of a spill-over effect observed in this trial. Firstly,
we did not aim to affect change in health practitioner behaviour with regards to treatment of
clinically incident diabetes patients. As such, training and support of general practitioners in
the intensive treatment of people with screen-detected diabetes may not be associated with any
benefits for individuals found with clinically-diagnosed diabetes in the same practices. An alter-
native explanation is that general practitioners in both trial groups improved their management
of screen-detected and clinically diagnosed diabetes patients. GPs taking part in ADDITION-
Denmark were self-selected and might have had a special interest in diabetes (28% of invited
GPs took part in the trial). The trial also took place against a background of increasing national
interest in screening and early treatment for diabetes, which might have encouraged practition-
ers to improve detection and management of CVD risk factors. Furthermore, we observed a
large and significant increase in redeemed cardio-protective treatment in both trial groups
during follow-up, suggesting that both intensive treatment and routine care GPs changed their
prescribing behaviour among clinically-diagnosed patients. Both trial groups had room for
improvement in GP prescribing e.g. only 78% of clinically-diagnosed individuals redeemed glu-
cose-lowering medication at the end of follow-up. This finding mirrors the main trial results
among screen-detected individuals, where both treatment groups received higher levels of car-
dio-protective medication by the end of follow-up and there were only modest differences in
levels of treatment and cardiovascular risk factors at the five-year health examination[6].
Strengths and limitations
The Danish registry system allows a unique investigation of the long-term experience of indi-
viduals diagnosed with clinically-incident diabetes in ADDITION-Denmark practices between
2001 and 2012. Trial groups were well balanced for patient level characteristics at baseline.
Outcome ascertainment was very robust. The Danish National Death Registry estimates 100%
coverage of mortality based on death certificates, while the National Patient Registry includes
99.4% of discharges from Danish hospitals. Deaths and incident CVD events were coded blind
to study group.
Our definition of clinically diagnosed diabetes was a proxy measure based on date of inclu-
sion in the Danish National Patient Register and redemption of glucose-lowering medication
at least twice within six months during the study period (2001 to 2009). While we did not have
formal clinical diagnosis of diabetes for each person included on the Register, a recent
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validation of the algorithm for including patients in the Register suggests that it has a sensitiv-
ity of95% and a positive predictive value of around 80% [16]. A further advantage of using
registry-defined diabetes is that the entire Danish population is covered by uniform inclusion
criteria and the dropout rate is nil. Since patients selected for the ADDITION-Denmark were
40 years of age at the time of inclusion of GP practices, we assume that the number of type 1
diabetes cases is likely to be low and similar in both groups.
While we were able to compare trends in redeemed medication to explore a potential effect
of the intervention on GP prescribing patterns, it would also have been useful to examine diet,
physical activity and smoking behavior to examine potential effects on motivation to change
lifestyle behaviour. However, these data are not available for individuals with clinically-diag-
nosed diabetes in ADDITION-Denmark practices.
In conclusion, there was no evidence of a spill-over effect from the intensive treatment of
people with screen-detected diabetes to those with clinically-diagnosed diabetes. The risk of
incident CVD and mortality did not differ between trial groups.
Acknowledgments
We gratefully acknowledge the contribution of all participants, practice nurses and general
practitioners in the ADDITION-Denmark study. With special thanks to Marianne Pedersen
(Department of Public Health, University of Aarhus) for her help retrieving data from Statis-
tics Denmark.
Author Contributions
Conceptualization: MC SJG RKS AS.
Data curation: MC MVS EMD.
Formal analysis: MC MVS RKS.
Funding acquisition: SJG TL AS.
Investigation: MC MVS SJG RKS DRW EMD TL AS.
Methodology: MC MVS SJG RKS TL AS.
Project administration: MC EMD TL AS.
Resources: MC MVS DRW TL AS.
Supervision: SJG DRW TL AS.
Validation: MC MVS EMD.
Writing – original draft: MC RKS.
Writing – review & editing: MC MVS SJG RKS DRW EMD TL AS.
References
1. 2016) Standards of Medical Care in Diabetes-2016. Diabetes Care 39 Suppl 1: S1–S2. 39/Supple-
ment_1/S1 [pii];.
2. Grol R, Grimshaw J (2003) From best evidence to best practice: effective implementation of change in
patients’ care. Lancet 362: 1225–1230. S0140-6736(03)14546-1 [pii];. doi: 10.1016/S0140-6736(03)
14546-1 PMID: 14568747
3. Cantillon P, Jones R (1999) Does continuing medical education in general practice make a difference?
BMJ 318: 1276–1279. PMID: 10231265
Investigation of a Spill-Over Effect in a Cluster RCT
PLOS ONE | DOI:10.1371/journal.pone.0170697 February 2, 2017 10 / 11
4. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, Whitty P, Eccles MP,
Matowe L, Shirran L, Wensing M, Dijkstra R, Donaldson C (2004) Effectiveness and efficiency of guide-
line dissemination and implementation strategies. Health Technol Assess 8: iii–72. 94-08-29 [pii].
5. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G (2000) The ADDI-
TION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbid-
ity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab
Disord 24 Suppl 3: S6–11.
6. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A, Sharp SJ, Simmons RK,
van den Donk M, Wareham NJ, Lauritzen T (2011) Effect of early intensive multifactorial therapy on 5-
year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-
Europe): a cluster-randomised trial. Lancet 378: 156–167. S0140-6736(11)60698-3 [pii];. doi: 10.1016/
S0140-6736(11)60698-3 PMID: 21705063
7. Rasmussen SS, Glumer C, Sandbaek A, Lauritzen T, Borch-Johnsen K (2008) General effect on high-
risk persons when general practitioners are trained in intensive treatment of type 2 diabetes. Scand J
Prim Health Care 26: 166–173. 795457059 [pii];. doi: 10.1080/02813430802264624 PMID: 18677673
8. Sibley JC, Sackett DL, Neufeld V, Gerrard B, Rudnick KV, Fraser W (1982) A randomized trial of con-
tinuing medical education. N Engl J Med 306: 511–515. doi: 10.1056/NEJM198203043060904 PMID:
7057858
9. Charles M, Ejskjaer N, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbaek A (2011) Prevalence of Neu-
ropathy and Peripheral Arterial Disease and the Impact of Treatment in People With Screen-Detected
Type 2 Diabetes: The ADDITION-Denmark study. Diabetes Care 34: 2244–2249. dc11-0903 [pii];. doi:
10.2337/dc11-0903 PMID: 21816977
10. Royal College of General practitioners in Denmark (1999) Type 2 diabetes in general practice—Diagno-
sis and treatment.
11. Royal College of General practitioners in Denmark. (2004) Type 2 diabetes in general practice—An evi-
dence based guideline.
12. Kildemoes HW, Sorensen HT, Hallas J (2011) The Danish National Prescription Registry. Scand J Pub-
lic Health 39: 38–41. 39/7_suppl/38 [pii];. doi: 10.1177/1403494810394717 PMID: 21775349
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comor-
bidity in longitudinal studies: development and validation. J Chronic Dis 40: 373–383. PMID: 3558716
14. Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, Halperin I, Vachon B, Ramsay T,
Manns B, Tonelli M, Shojania K (2012) Effectiveness of quality improvement strategies on the manage-
ment of diabetes: a systematic review and meta-analysis. Lancet 379: 2252–2261. S0140-6736(12)
60480-2 [pii];. doi: 10.1016/S0140-6736(12)60480-2 PMID: 22683130
15. Lauritzen T, Sandbaek A, Carlsen AH, Borch-Johnsen K (2012) All-cause mortality and pharmacologi-
cal treatment intensity following a high risk screening program for diabetes. A 6.6 year follow-up of the
ADDITION study, Denmark. Prim Care Diabetes 6: 193–200. S1751-9918(12)00047-2 [pii];. doi: 10.
1016/j.pcd.2012.04.005 PMID: 22595031
16. Green A, Sortso C, Jensen PB, Emneus M (2015) Validation of the danish national diabetes register.
Clin Epidemiol 7: 5–15. clep-7-005 [pii]. doi: 10.2147/CLEP.S72768 PMID: 25565889
Investigation of a Spill-Over Effect in a Cluster RCT
PLOS ONE | DOI:10.1371/journal.pone.0170697 February 2, 2017 11 / 11
